FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 217 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Vegetarian Recipes September 4, 2020 Alternatives for Outdoor Foods October 16, 2020 Two Large Studies with New Screening Tests Show Promise for Increasing... March 18, 2024 Mom Wants Disney To Ban Childless Adults From Their Theme Parks July 29, 2019 Load more HOT NEWS 5-Yr-Old Has Cutest Celebration With Big Brother After Being Declared Cancer-Free. Can cancer cells communicate? Coverage for Breast Cancer Genetic Marker Testing is Still Being Denied... ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European...
